SCHEMBL1047387

SCHEMBL1047387

NS(=O)(=O)c1ccccc1Nc1cc2cc[nH]c(=O)c2c(Nc2ccc(N3CCOCC3)cc2)n1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 12/20 0.77
JAK2 O60674 4/20 0.43
SYK P43405 3/20 0.43
MAP4K1 Q92918 1/20 0.43
TTBK1 Q5TCY1 1/20 0.42
TTBK2 Q6IQ55 1/20 0.42
LYN P07948 2/20 0.41
FLT3 P36888 1/20 0.41
KCNH2 Q12809 1/20 0.41
JAK3 P52333 1/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TTK P33981 1/20 0.40
MAPKAPK5 Q8IW41 1/20 0.40
CDK2 P24941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1049000 0.92 ZAP70 (0.73) ZAP70JAK2SYKMAP4K1TTBK1
SCHEMBL1049400 0.90 ZAP70 (0.70) ZAP70JAK2SYKMAP4K1KCNH2
SCHEMBL1044892 0.89 ZAP70 (0.69) ZAP70JAK2SYKMAP4K1LYN
SCHEMBL1047800 0.89 ZAP70 (0.67) ZAP70JAK2SYKMAP4K1TTBK1
SCHEMBL1046926 0.89 ZAP70 (0.69) ZAP70JAK2SYKMAP4K1TTBK1
SCHEMBL1047728 0.89 ZAP70 (0.69) ZAP70JAK2SYKMAP4K1TTK
SCHEMBL1049110 0.89 ZAP70 (0.68) ZAP70JAK2SYKMAP4K1LYN
SCHEMBL1045837 0.88 ZAP70 (0.67) ZAP70JAK2SYKMAP4K1MEN1
SCHEMBL1047730 0.88 ZAP70 (0.67) ZAP70JAK2SYKMAP4K1TTBK1
SCHEMBL1043374 0.87 ZAP70 (0.68) ZAP70TTBK1TTBK2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
CN-101990539-A Compounds and compositions as kinase inhibitors IRM LLC 2011-03-23 CN claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
CN-101990539-A Compounds and compositions as kinase inhibitors IRM LLC 2011-03-23 CN disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET ZAP70 4/4885JAK2 63/4885SYK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.